Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

doi:10.1016/S0304-3940(99)00617-5

Neuroscience Letters

Volume 273, Issue 1, 24 September 1999, Pages 5-8

https://doi.org/10.1016/S0304-3940(99)00617-5 Get rights and content

Abstract

We studied CSF-tau and CSF-Aβ42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6–27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Aβ42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.

Section snippets

Acknowledgements

This work was supported by grants from the Swedish Medical Research Council (grants Nos. 12103 and 11560); Alzheimerfonden; Stiftelsen för Gamla Tjänarinnor; Tore Nilssons Fond; Norrbottens Läns Landsting; Svenska Läkaresällskapet and Åke Wibergs Stiftelse.

References (20)

M. Folstein et al.
‘Mini-Mental State’ A practical method for grading the cognitive state of patients for the clinician
J. Psychiatr. Res.
(1975)
T. Iwatsubo et al.
Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific A(monocloncals: evidence that an initially deposited species is Aβ42(43)
Neuron
(1994)
M. Riemenschneider et al.
Cerebrospinal protein tau is elevated in early Alzheimer's disease
Neurosci. Lett.
(1996)
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn., American Psychiatric...
N. Andreasen et al.
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study
J. Neurol. Neurosurg. Psychiatry
(1998)
N. Andreasen et al.
Prevalence and incidence of memory recall disturbances in a geographically defined general population. The Piteȧ Dementia Project
Neuroepidemiology
(1999)
N. Andreasen et al.
Cerebrospinal fluid β-amyloid_(1–42) in Alzheimer's disease: differences between early- and late-onset AD and stability during the course of disease
Arch. Neurol.
(1999)
K. Blennow et al.
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease?
Mol. Chem. Neuropathol.
(1995)
L. Davies et al.
A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques
Neurology
(1988)
D. Galasko et al.
Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
Neurology
(1997)

There are more references available in the full text version of this article.

Cited by (241)

Recent advances in electrochemical biosensors for the detection of Aβ42, a biomarker for Alzheimer disease diagnosis
2023, TrAC - Trends in Analytical Chemistry
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with a long latency in the "prodromal" stage, for which there are currently no effective treatments. It is generally accepted that accurate diagnosis and subsequent treatment in the early stages of AD may lead to better therapeutic outcomes. Detection of body fluid biomarkers is an effective strategy for early AD diagnosis. Among them, amyloid β(1–42) (Aβ42), as one of the most important biomarkers of AD, plays a key role in the progression of AD. Currently, electrochemical biosensors offer many advantages in monitoring Aβ42 because they are fast, portable, and capable of on-site analysis. This article provides an overview of the dynamics of Aβ42 levels in biological fluids as AD progresses, followed by a detailed description of the design and analytical performance of various electrochemical sensors. Finally, the challenges of electrochemical sensors for AD diagnosis are discussed, and prospects and trends are outlined.
The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death
2022, Brain Research Bulletin
The tau protein (τ) is one of the two hallmark proteins of Alzheimer’s disease (AD) together with the amyloid β protein (Aβ). In contrast to Aβ, abnormally phosphorylated τ (p-τ) can also be found in non-AD tauopathies. In AD, p-τ is the main component of intraneuronal neurofibrillary tangles, which result from aggregation of abnormally phosphorylated and folded τ. In this review, we discuss the role of p-τ pathology in Alzheimer’s disease considering neuropathological, biochemical, cellular, animal model, and clinical findings. We discuss the relationship between p-τ and other AD-related proteins such as Aβ and transactive response DNA-binding protein 43 (TDP-43). In light of the current state of knowledge, we conclude that p-τ aggregation known as primary age-related tauopathy (PART) may represent a prerequisite for the development of AD rather that a downstream effect of Aβ toxicity. However, Aβ as well as TDP-43 pathology appear to accelerate accumulation and propagation of p-τ pathology once initiated, ultimately leading to the full-blown picture of AD. In this context, τ seeds can induce granulovacuolar degeneration (GVD), AD-typical lesions in which the activated necrosome – required for the execution of necroptosis, a programmed form of cell death - can be found. Moreover, necrosome-exhibiting GVD is associated with a decreased neuronal density. Thus, we speculate that p-τ pathology is a major driver for neuron loss in AD via GVD-mediated necroptosis. Overall, p-τ seems to play a central role in AD as it appears to constitute a prerequisite for AD development which can then be accelerated by co-factors. This would fit in a probabilistic model of AD, in which the presence and severity of the respective co-factors such as Aβ, TDP-43, and others contribute separately to AD pathogenesis as probabilistic factors with a certain weight.
A survey on machine and statistical learning for longitudinal analysis of neuroimaging data in Alzheimer's disease
2020, Computer Methods and Programs in Biomedicine
Background and Objectives: Recently, longitudinal studies of Alzheimer’s disease have gathered a substantial amount of neuroimaging data. New methods are needed to successfully leverage and distill meaningful information on the progression of the disease from the deluge of available data. Machine learning has been used successfully for many different tasks, including neuroimaging related problems. In this paper, we review recent statistical and machine learning applications in Alzheimer’s disease using longitudinal neuroimaging. Methods: We search for papers using longitudinal imaging data, focused on Alzheimer’s Disease and published between 2007 and 2019 on four different search engines. Results: After the search, we obtain 104 relevant papers. We analyze their approach to typical challenges in longitudinal data analysis, such as missing data and variability in the number and extent of acquisitions. Conclusions: Reviewed works show that machine learning methods using longitudinal data have potential for disease progression modelling and computer-aided diagnosis. We compare results and models, and propose future research directions in the field.
AD biomarker discovery in CSF and in alternative matrices
2019, Clinical Biochemistry
Core Alzheimer's Disease (AD) biomarkers are the cerebrospinal fluid (CSF) proteins amyloid β42 and β40, and the tau proteins, total and phosphorylated. Their use is recommended by research guidelines for diagnostic purpose and for stratification of patients for clinical trials. However, novel potential biomarkers are needed, which can mirror risk factors and other different mechanisms of the disease, hopefully in less invasive biological fluids or matrices. Studies on blood, urine, saliva, tears gave promising results, and several novel molecules have been identified, as potential brain derived biomarkers, thanks to the development of novel ultrasensitive technologies. In this review, we discuss about advantages and limits of the classical CSF biomarkers of AD, as well as of novel CSF candidate biomarkers and recent promises from alternative matrices.
Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study
2019, Alzheimer's and Dementia
Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined.
We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples. Diagnoses were subjective cognitive decline (n = 75), mild cognitive impairment (n = 128), and AD dementia (n = 110), and a group of cognitively unimpaired subjects (n = 154) were also included. We measured baseline and follow-up CSF levels of total tau (t-tau), phosphorylated tau (p-tau), YKL-40, and neurofilament light (NfL). Median CSF sampling interval was 2.1 years.
CSF levels of t-tau, p-tau, NfL, and YKL-40 were 2% higher per each year of baseline age in controls (P <.001). In AD, t-tau levels were 1% lower (P <.001) and p-tau levels did not change per each year of baseline age. Longitudinally, only NfL (P <.001) and YKL-40 (P <.02) increased during the study period.
All four CSF biomarkers increase with age, but this effect deviates in AD for t-tau and p-tau.
Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer’s disease: racial differences
2024, Neurological Sciences

View all citing articles on Scopus

View full text

Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

Abstract

Section snippets

Acknowledgements

J. Psychiatr. Res.

Neuron

Neurosci. Lett.

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

J. Neurol. Neurosurg. Psychiatry

Prevalence and incidence of memory recall disturbances in a geographically defined general population. The Piteȧ Dementia Project

Neuroepidemiology

Cerebrospinal fluid β-amyloid(1–42) in Alzheimer's disease: differences between early- and late-onset AD and stability during the course of disease

Arch. Neurol.

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease?

Mol. Chem. Neuropathol.

A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques

Neurology

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

Neurology

Cerebrospinal fluid β-amyloid_(1–42) in Alzheimer's disease: differences between early- and late-onset AD and stability during the course of disease